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Pounds?
Unknown woman: Yes sir, I think I would.
Sir Winston: Well, how about 1 Pound?
Unknown woman: Winston! What sort of woman do you
think I am?
Sir Winston: Madam, that matter has already been solved.
Now we’re just haggling over your price.
As a member of the pharmacy and medical device
committee at a leading hospital, you are part of a
discussion considering whether or not varieties of cor-
onary artery stents should be limited and if so which
ones should be chosen. The hospital representative has
endorsed a particular stent from a contractual cost
basis. The cardiologist member strongly recommends a
particular company’s product. His stated reasoning
is that the recommended manufacturer contributes
heavily to the Penumbral Heart and Vascular Founda-
tion, which funds various local research projects. A
number of local leading physician members are on the
company’s suggested speaker panels and clinical advi-
sory board. The cost of the stent recommended by the
cardiologist member would be higher than using an-
other product, but it is argued that the prestige of the
medical staff and the institution would decline with a
possible reduction in referrals. What should be done?
A. Everyone has biases. Approve the recommendations of
your cardiology colleague.
B. Let the deciding factor be a poll of all the cardiologists
practicing at your hospital.
C. Demand that the cardiologist recuse herself and make
the decision on the recommendations of cardiologist
advisors who have no conflicts.
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1126D. Conflicts aside, the product must be the best or your
nationally known colleague would not be using it.
Approve his recommendations.
E. Report the matter to the ethics committee of your
county medical society.
These days, there seems to be a constant bombardment
of dark social ills brought to light by the daily news,
including family violence, hate crimes, public malfeasance,
and corporate thievery. Whether this moral degeneracy is
newly hatched or was conveniently ignored in the past, one
can only hope the increased level of media awareness can
lessen these immoralities. Physicians are hardly immune
from the press finding sewage in their mainstreams, usually
involving professional conflicts of interest.1-4 These profes-
sional conflicts of interest always involve some medium of
exchange, and the innovative ways some physicians appear
willing to compromise professional integrity to supplement
their already comfortable incomes constantly astonishes.
Reed Abelson, one of America’s most talented medical
sensationalists, reporting for the New York Times, pub-
lished a recent article entitled, “Charities Tied to Doctors
get Industry Gifts.”2 The article opens not with a deflect-
able jab but with a solid right cross to the ethical snout of
medicine, beginning with the story of a cardiologist report-
ing at a conference in March this year that a $14,000
ultra-filtration device removed fluid better in heart failure
patients than diuretics. Surprise! And a Ferrari accelerates
faster than a Ford but to what avail? Although prominent
researchers questioned the study’s conclusions, the pre-
senting doctor remained adamant. “We believe these re-
sults challenge current medical practice and recommenda-
tions,” said Dr X, who predicted many patients might
benefit.”2 Dr X did not disclose that the company making
the device had donated $180,000 to a foundation she and
50 associates staffed, funded the study, and paid her a salary
as a consultant, three conflictual, possibly ethical strikes.
Wedonot deny that this therapy could eventually become
the standard of care, but look at the implications if adopted.
According to the National Center for Health Statistics, 1.09
million patients were discharged (not admitted) from hospi-
tals in the United States with a diagnosis of heart failure in
2003,5 and because of an aging population, the number is
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have added a $15.3 billion bloat to health care. A remark
attributed to Everett Dirksenmockedwell those who spend
huge, “A billion here, a billion there, and pretty soon
you’re talking real money.”
The science and practice of the group, the foundation,
and the data may well be legitimate, but there are quite a
number of possible improprieties. Let us count the ways:
personal influencing of the individual physician’s research;
influencing the general group practice; an affront to legiti-
mate charities such as foundations of major medical societ-
ies and colleges; a questionable business practice of the
medical company sponsors; a possible tax loophole when
doing little to deserve special status; and last, but not at all
least, a platform for disbursing conflicted information
about medical practice.
In previous articles we decried industries’ intrusions on
medicine’s professionalism.6-9 Consider the least objec-
tionable financial relationship, receiving seemingly insignif-
icant gifts from medical companies.7 What difference can a
free medical book, a nice pen or pencil, or dinner to discuss
the latest drugs or devices make? It can cloud the physi-
cian’s medical judgment; that’s what. It can make one
choose a more expensive therapy without patient benefit,
expand unsupported indications for therapies, or lead to
the acceptance of the drug rep’s pitch as the last word
without further study. Waud10 had the temerity to write
that every kind of gift from the medical industry to physi-
cians was a bribe, an inducement for doctors to buy instru-
ments, contraptions, and medications that someone else
finally gets billed for. This is known as baksheesh to anyone
traveling in the mid-east, a word sharing its etymological
root with nebbish, a descriptive insult of personal character
that assumes allowing one’s moral behavior to be decided
by bribes is cowardly.
The next item on the list to trot out are the paid pseudo-
consultancies and “marketing research” payments.9 “Some-
where along the way, though, the medical manufacturers’
marketing departments shouldered their way into the process,
and introduced the techniques of advertising and salesman-
ship to what medical professionals had been led to believe
was a relationship built on their scientific and clinical exper-
tise. Though told otherwise, it was no longer just the
doctor’s expert opinions and research programs that were
sought, it was his influence as a sales broker for expensive
products he ordered at his patients’ expense.” Industrial
money, disguised as research support, can easily be slipped
into the marketing department, as the subject of the New
York Times exposé appears to have done.3 A paid medical
consultant necessarily becomes the functional equivalent of
a company employee, and companies, not surprisingly,
expect their employees’ loyalty, the thorny rose of commer-
cialization.
But why bring the matter of physician/industrial con-
flicts of interest forward once again? Because the formation
of tax-free charitable foundations is the latest, perhaps
greatest, conflict of interest blemish on professionalism yet
devised. Payments to such foundations create possible con-flicts of interest, though not in the direct form that pay-
ments to physicians as consultants or members of speakers’
bureaus do. Setting up such foundations is at risk for
becoming a subterfuge conceived of by physicians, not
industry, that could lead to the plethora of unethical be-
haviors identified above, touching on every aspect of a
physician’s professional life. In this scenario, the physician’s
economic self-interest in the foundation is substantial if he
is receiving research support from it. His relationship with
the company in question is thus an indirect conflict of
interest, but no less substantial as a result. Foundations can
become legal vehicles for transferring industry money to
physicians that flies beneath the moral radar by posing as a
charitable undertaking. When receiving funds from a
“foundation,” one may delude themselves into thinking
that because of the intermediary there is no conflict, but
only a psychosis would allow forgetting who funded the
“foundation” and who could withdrawal future funding.
There have been numerous examples of gross distor-
tions when scientific objectivity has not been scrupulously
maintained. To prevent this problem, academic health cen-
ters have established conflict of interest policies, but these
usually do not address indirect conflicts of interest that are
created when payments are “laundered” to parties or enti-
ties other than the investigator.11 The newly emerging
forms of indirect conflicts of interest need to be disclosed to
professional organizations and hospitals and responsibly
managed so that they do not distort the decision-making
processes of health care organizations.
The syllogism for option A would read: All humans
have biases and must make decisions regardless. All physi-
cians are humans. Therefore, physicians must, because of
their human nature, make biased decisions. This assumes
that conflicts of interest are both unavoidable and also that
they cannot be responsibly managed. The conflict of inter-
est in this case is avoidable; other conflict-free cardiologists
could be asked to advise the committee. Important institu-
tional decisions should be made by individuals who are
unbiased on the specific matter being discussed.
Option B is what used to be done when cost-plus
reimbursement was in vogue. Then the hospital adminis-
trators spared no expense in having huge inventories of
different types of prosthetic joints, heart valves, vascular
grafts, and other supplies, but we live in a different world
today. Provided there is no evidence-based clinical advan-
tage of one therapy over another, cost merits consideration,
being important enough to be mentioned first in the Amer-
ican College of Surgeons Task Force on Professionalism’s
recommendations.12 Science’s foundation is not democ-
racy. It is unlikely that evidence-based consensus would
be reached by taking a poll. In addition, taking a poll does
not responsibly manage conflicts of interest; depending
upon the conflicts of interest of those polled, associated
politicking might lead to less effective management of
conflicts of interest.
Option D assumes that conflicts of interest are indi-
rectly proportional to clinical competence when, in fact,
“human nature” may make it just the opposite. The higher
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may believe they are. The faulty reasoning of this option
undermines it as a responsible strategy for managing con-
flicts of interest.
Option E is very premature. There is no evidence of the
cardiologist behaving improperly. Anyone who serves on
institutional advisory committees has the obligation to
contribute their expertise and advice toward questions in
their sphere of knowledge. Serious unmanaged conflicts of
interest are morally wrong without proof of wrongdoing
but are not censurable per se.
Financial conflicts of interest disorder scientific objec-
tivity and they abound.9 Some knowledgeable sociologists
describe the current societal state as a “creed of greed,” and
from the incessant trials of top level corporate crooks,
doubt of this resides only with the most naive and unin-
formed.13 Whatever, retention of medicine’s exalted pro-
fessional status, inherited from physician’s collective efforts
across the previous centuries, conflicts of interest need to be
dealt with by more than simple disclosure, although even
simple disclosure has been a repeated problem with authors
at one of the most prestigious American journals.14 The
editor of the Journal of the American Medical Association,
Dr DeAngelis, publishes names of nondisclosing violators,
when discovered, and notifies deans at their medical
schools. But continued failures of authors to disclose have
led criticisms of her efforts. Perhaps, a special journal for
publishing conflicted data is needed with the articles avail-
able for citing only after nonconflicted confirming articles
are published.
To protect the scientific and ethical integrity of the
committee’s deliberations and recommendations and of
the hospital’s purchasing practices and policies, the con-
flicted cardiologist should not be allowed to participate in
deliberations and recommendations. There is surely exper-
tise in his specialty from colleagues without direct or indi-rect conflicts of interest. If no such expertise is available
within the medical staff of the hospital, it should be ob-
tained on a consultancy basis. Option C, rarely chosen in
practice, is our selection.
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